MW01-2-151SRM

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 562365

CAS#: 886208-65-7 (free base)

Description: MW01-2-151SRM is a CNS-penetrant, selective restorer of injury- or disease-induced overproduction of proinflammatory cytokines towards homeostasis. It also acts as a selective suppressor of beta amyloid A.


Chemical Structure

img
MW01-2-151SRM
CAS# 886208-65-7 (free base)

Theoretical Analysis

MedKoo Cat#: 562365
Name: MW01-2-151SRM
CAS#: 886208-65-7 (free base)
Chemical Formula: C19H20N6
Exact Mass: 332.17
Molecular Weight: 332.411
Elemental Analysis: C, 68.65; H, 6.06; N, 25.28

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 886208-65-7 (free base)   924909-75-1 (2HCl)  

Synonym: MW01-2-151SRM; MW01 2 151SRM; MW012151SRM; MW151; MW-151; MW 151; Minozac free base

IUPAC/Chemical Name: 2-(4-(4-Methyl-6-phenylpyridazin-3-yl)piperazin-1-yl)pyrimidine

InChi Key: ASVQCPUSQNFHHU-UHFFFAOYSA-N

InChi Code: InChI=1S/C19H20N6/c1-15-14-17(16-6-3-2-4-7-16)22-23-18(15)24-10-12-25(13-11-24)19-20-8-5-9-21-19/h2-9,14H,10-13H2,1H3

SMILES Code: CC1=CC(C2=CC=CC=C2)=NN=C1N3CCN(C4=NC=CC=N4)CC3

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 332.41 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Webster SJ, Van Eldik LJ, Watterson DM, Bachstetter AD. Closed head injury in an age-related Alzheimer mouse model leads to an altered neuroinflammatory response and persistent cognitive impairment. J Neurosci. 2015 Apr 22;35(16):6554-69. doi: 10.1523/JNEUROSCI.0291-15.2015. PubMed PMID: 25904805; PubMed Central PMCID: PMC4405562.

2: Bachstetter AD, Webster SJ, Goulding DS, Morton JE, Watterson DM, Van Eldik LJ. Attenuation of traumatic brain injury-induced cognitive impairment in mice by targeting increased cytokine levels with a small molecule experimental therapeutic. J Neuroinflammation. 2015 Apr 10;12:69. doi: 10.1186/s12974-015-0289-5. PubMed PMID: 25886256; PubMed Central PMCID: PMC4396836.

3: Macauley SL, Wong AM, Shyng C, Augner DP, Dearborn JT, Pearse Y, Roberts MS, Fowler SC, Cooper JD, Watterson DM, Sands MS. An anti-neuroinflammatory that targets dysregulated glia enhances the efficacy of CNS-directed gene therapy in murine infantile neuronal ceroid lipofuscinosis. J Neurosci. 2014 Sep 24;34(39):13077-82. doi: 10.1523/JNEUROSCI.2518-14.2014. PubMed PMID: 25253854; PubMed Central PMCID: PMC4172802.

4: Jenrow KA, Brown SL, Kolozsvary AJ, Lapanowski K, Kim JH. Time-dependent inhibition of pan-inflammatory cytokines mitigates radiation-induced skin injury in mice. Radiat Res. 2014 Sep;182(3):316-21. doi: 10.1667/RR13711.1. Epub 2014 Aug 6. PubMed PMID: 25098729.

5: Jenrow KA, Brown SL, Lapanowski K, Naei H, Kolozsvary A, Kim JH. Selective inhibition of microglia-mediated neuroinflammation mitigates radiation-induced cognitive impairment. Radiat Res. 2013 May;179(5):549-56. doi: 10.1667/RR3026.1. Epub 2013 Apr 5. PubMed PMID: 23560629; PubMed Central PMCID: PMC3673739.

6: Bachstetter AD, Norris CM, Sompol P, Wilcock DM, Goulding D, Neltner JH, St Clair D, Watterson DM, Van Eldik LJ. Early stage drug treatment that normalizes proinflammatory cytokine production attenuates synaptic dysfunction in a mouse model that exhibits age-dependent progression of Alzheimer's disease-related pathology. J Neurosci. 2012 Jul 25;32(30):10201-10. doi: 10.1523/JNEUROSCI.1496-12.2012. PubMed PMID: 22836255; PubMed Central PMCID: PMC3419360.